PHYSICIAN ASSISTANT PRACTICE

Illinois General Assembly - Full Text of SB0271

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of SB0271

Home

Legislation

Full Text

SB0271 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Senate Amendment 001

Printer Friendly Version

Introduced

Senate Amendment 001

Open PDF

104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026
SB0271

Introduced 1/24/2025, by Sen. Javier L. Cervantes

SYNOPSIS AS INTRODUCED:

225 ILCS 95/4

from Ch. 111, par. 4604
225 ILCS 95/6

from Ch. 111, par. 4606
225 ILCS 95/7

from Ch. 111, par. 4607
225 ILCS 95/7.5
225 ILCS 95/7.7
225 ILCS 95/7.8 new
225 ILCS 95/7.9 new
225 ILCS 95/20

from Ch. 111, par. 4620
225 ILCS 95/21

from Ch. 111, par. 4621
720 ILCS 570/102

from Ch. 56 1/2, par. 1102
720 ILCS 570/303.05

Amends the Physician Assistant Practice Act of 1987. Provides that a
physician assistant may prescribe, dispense, order, administer, and
procure drugs and medical devices without delegation of authority by a
physician. Provides that a physician assistant may practice without a
written collaborative agreement. Provides that a physician assistant who
files with the Department of Financial and Professional Regulation a
notarized attestation of completion of at least 250 hours of continuing
education or training and at least 2,000 hours of clinical experience
after first attaining national certification shall not require a written
collaborative agreement to practice. Makes changes in provisions
concerning definitions; physician assistant title; collaboration
requirements; written collaborative agreements, prescriptive authority,
and physician assistants in hospitals, hospital affiliates, or ambulatory
surgical treatment centers; inactive status; limitations; and grounds for
disciplinary action. Amends the Illinois Controlled Substances Act to make
corresponding changes.
LRB104 03116 AAS 13137 b

A BILL FOR

SB0271
LRB104 03116 AAS 13137 b
1

AN ACT concerning regulation.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The Physician Assistant Practice Act of 1987 is
5
amended by changing Sections 4, 6, 7, 7.5, 7.7, 20, and 21 and
6
by adding Sections 7.8 and 7.9 as follows:

7

(225 ILCS 95/4)

(from Ch. 111, par. 4604)
8

(Section scheduled to be repealed on January 1, 2028)
9

Sec. 4.
Definitions.
In this Act:
10

1. "Department" means the Department of Financial and
11
Professional Regulation.
12

2. "Secretary" means the Secretary of Financial and
13
Professional Regulation.
14

3. "Physician assistant" means any person not holding an
15
active license or permit issued by the Department pursuant to
16
the Medical Practice Act of 1987 who has been certified as a
17
physician assistant by the National Commission on
the

18
Certification of Physician Assistants or
an
equivalent
19
successor agency
.

and performs procedures in collaboration
20
with a physician as defined in this Act. A physician assistant
21
may perform such procedures within the specialty of the
22
collaborating physician, except that such physician shall
23
exercise such direction, collaboration, and control over such

SB0271
- 2 -
LRB104 03116 AAS 13137 b
1
physician assistants as will assure that patients shall
2
receive quality medical care. Physician assistants shall be
3
capable of performing a variety of tasks within the specialty
4
of medical care in collaboration with a physician.
5
Collaboration with the physician assistant shall not be
6
construed to necessarily require the personal presence of the
7
collaborating physician at all times at the place where
8
services are rendered, as long as there is communication
9
available for consultation by radio, telephone or
10
telecommunications within established guidelines as determined
11
by the physician/physician assistant team. The collaborating
12
physician may delegate tasks and duties to the physician
13
assistant. Delegated tasks or duties shall be consistent with
14
physician assistant education, training, and experience. The
15
delegated tasks or duties shall be specific to the practice
16
setting and shall be implemented and reviewed under a written
17
collaborative agreement established by the physician or
18
physician/physician assistant team. A physician assistant,
19
acting as an agent of the physician, shall be permitted to
20
transmit the collaborating physician's orders as determined by
21
the institution's by-laws, policies, procedures, or job
22
description within which the physician/physician assistant
23
team practices. Physician assistants shall practice only in
24
accordance with a written collaborative agreement.
25

Any person who holds an active license or permit issued
26
pursuant to the Medical Practice Act of 1987 shall have that

SB0271
- 3 -
LRB104 03116 AAS 13137 b
1
license automatically placed into inactive status upon
2
issuance of a physician assistant license. Any person who
3
holds an active license as a physician assistant who is issued
4
a license or permit pursuant to the Medical Practice Act of
5
1987 shall have his or her physician assistant license
6
automatically placed into inactive status.

7

3.5. "Physician assistant practice" means the performance
8
of
any legal medical service for which the physician assistant
9
has been prepared by the physician assistant's education,
10
training, and experience and is competent to perform as
11
determined through an employment agreement or the
12
credentialing and privileging system of a licensed facility.
13
Medical and surgical services provided by physician assistants
14
include, but are not limited to:
15

(A) obtaining and performing comprehensive health
16

histories and physical examinations;
17

(B) evaluating, diagnosing, managing, and providing
18

medical treatment;
19

(C) ordering, performing, and interpreting diagnostic
20

studies and therapeutic procedures;
21

(D) educating patients on health promotion and disease
22

prevention;
23

(E) providing consultation upon request;
24

(F) writing medical orders;
25

(G) prescribing, dispensing, ordering, administering,
26

and procuring drugs and medical devices; and

SB0271
- 4 -
LRB104 03116 AAS 13137 b
1

(H) assisting in surgery.

procedures within the
2

specialty of the collaborating physician. Physician
3

assistants shall be capable of performing a variety of
4

tasks within the specialty of medical care of the
5

collaborating physician. Collaboration with the physician
6

assistant shall not be construed to necessarily require
7

the personal presence of the collaborating physician at
8

all times at the place where services are rendered, as
9

long as there is communication available for consultation
10

by radio, telephone, telecommunications, or electronic
11

communications. The collaborating physician may delegate
12

tasks and duties to the physician assistant. Delegated
13

tasks or duties shall be consistent with physician
14

assistant education, training, and experience. The
15

delegated tasks or duties shall be specific to the
16

practice setting and shall be implemented and reviewed
17

under a written collaborative agreement established by the
18

physician or physician/physician assistant team. A
19

physician assistant shall be permitted to transmit the
20

collaborating physician's orders as determined by the
21

institution's bylaws, policies, or procedures or the job
22

description within which the physician/physician assistant
23

team practices. Physician assistants shall practice only
24

in accordance with a written collaborative agreement,
25

except as provided in Section 7.5 of this Act.

26

4. "Board" means the
Illinois State Medical Board

Medical

SB0271
- 5 -
LRB104 03116 AAS 13137 b
1
Licensing Board constituted under the Medical Practice Act of
2
1987
.
3

5. (Blank).
4

6. "Physician" means a person licensed to practice
5
medicine in all of its branches under the Medical Practice Act
6
of 1987.
7

7. "Collaborating physician" means the physician who,
8
within his or her specialty and expertise, may delegate a
9
variety of tasks and procedures to the physician assistant.
10
Such tasks and procedures shall be delegated in accordance
11
with a written collaborative agreement
when the agreement is
12
required under this Act
.
13

8. (Blank).
14

9. "Address of record" means the designated address
15
recorded by the Department in the applicant's
application file

16
or
the
licensee's
application file or
license file
, as

17
maintained by the Department's licensure maintenance unit.
18

10. "Hospital affiliate" means a corporation, partnership,
19
joint venture, limited liability company, or similar
20
organization, other than a hospital, that is devoted primarily
21
to the provision, management, or support of health care
22
services and that directly or indirectly controls, is
23
controlled by, or is under common control of the hospital. For
24
the purposes of this definition, "control" means having at
25
least an equal or a majority ownership or membership interest.
26
A hospital affiliate shall be 100% owned or controlled by any

SB0271
- 6 -
LRB104 03116 AAS 13137 b
1
combination of hospitals, their parent corporations, or
2
physicians licensed to practice medicine in all its branches
3
in Illinois. "Hospital affiliate" does not include a health
4
maintenance organization regulated under the Health
5
Maintenance Organization Act.
6

11. "Email address of record" means the designated email
7
address recorded by the Department in the applicant's
8
application file or the licensee's license file, as maintained
9
by the Department's licensure maintenance unit.
10

12. "Federally qualified health center" means a health
11
center funded under Section 330 of the federal Public Health
12
Service Act.
13
(Source: P.A. 102-1117, eff. 1-13-23; 103-65, eff. 1-1-24
.)

14

(225 ILCS 95/6)

(from Ch. 111, par. 4606)
15

(Section scheduled to be repealed on January 1, 2028)
16

Sec. 6.
Physician assistant title.
17

(a) No physician assistant shall use the title of doctor,
18
physician, or associate with his or her name or any other term
19
that would indicate to other persons that he or she is
20
qualified to engage in the general practice of medicine.
21

(b) A physician assistant shall verbally identify himself
22
or herself as a physician assistant, including
, when
23
applicable,
specialty certification, to each patient.
24

(c) Nothing in this Act shall be construed to relieve a
25
physician assistant of the professional or legal

SB0271
- 7 -
LRB104 03116 AAS 13137 b
1
responsibility for the care and treatment of persons attended
2
by him or her.
3

(d)
(Blank).

The collaborating physician shall file with
4
the Department notice of employment, discharge, or
5
collaboration with a physician assistant within 60 days of
6
employment, discharge, or assumption of collaboration with a
7
physician assistant. Nothing in this Section shall prevent a
8
physician assistant from beginning his or her employment
9
before the notice of employment or collaboration has been
10
filed.

11
(Source: P.A. 102-735, eff. 1-1-23
.)

12

(225 ILCS 95/7)

(from Ch. 111, par. 4607)
13

(Section scheduled to be repealed on January 1, 2028)
14

Sec. 7.
Collaboration requirements.
15

(a) A written collaborative agreement is required for all
16
physician assistants engaged in clinical practice prior to
17
satisfying the requirements of Section 7.9, except for
18
physician assistants who practice in a hospital, hospital
19
affiliate, federally qualified health center, or ambulatory
20
surgical treatment center as provided in Section 7.7.

21

(b)

(a)
A collaborating physician shall determine the
22
number of physician assistants to collaborate with, provided
23
the physician is able to provide adequate collaboration as
24
outlined in the written collaborative agreement required under
25
Section 7.5 of this Act and consideration is given to the

SB0271
- 8 -
LRB104 03116 AAS 13137 b
1
nature of the physician's practice, complexity of the patient
2
population, and the experience of each physician assistant. A
3
collaborating physician may collaborate with a maximum of 7
4
full-time equivalent physician assistants as described in
5
Section 54.5 of the Medical Practice Act of 1987. As used in
6
this Section, "full-time equivalent" means the equivalent of
7
40 hours per week per individual. Physicians and physician
8
assistants who work in a hospital, hospital affiliate,
9
federally qualified health center, or ambulatory surgical
10
treatment center as defined by Section 7.7 of this Act are
11
exempt from the collaborative ratio restriction requirements
12
of this Section. A physician assistant shall be able to hold
13
more than one professional position. A collaborating physician
14
shall file a notice of collaboration of each physician
15
assistant according to the rules of the Department.
16

(c)
Physician assistants shall collaborate only with
17
physicians as defined in this Act who are engaged in clinical
18
practice, or in clinical practice in public health or other
19
community health facilities.
20

(d)
Nothing in this Act shall be construed to limit the
21
delegation of tasks or duties by a physician to a nurse or
22
other appropriately trained personnel.
23

(e)
Nothing in this Act shall be construed to prohibit the
24
employment of physician assistants by a hospital, nursing home
25
or other health care facility where such physician assistants
26
function
with

under
a collaborating physician.

SB0271
- 9 -
LRB104 03116 AAS 13137 b
1

(f)
A physician assistant may be employed by a practice
2
group or other entity employing multiple physicians at one or
3
more locations. In that case, one of the physicians practicing
4
at a location shall be designated the collaborating physician.
5
The other physicians with that practice group or other entity
6
who practice in the same general type of practice or specialty
7
as the collaborating physician may collaborate with the
8
physician assistant with respect to their patients.
9

(g)

(b)
A physician assistant licensed in this State, or
10
licensed or authorized to practice in any other U.S.
11
jurisdiction or credentialed by his or her federal employer as
12
a physician assistant, who is responding to a need for medical
13
care created by an emergency or by a state or local disaster
14
may render such care that the physician assistant is able to
15
provide without collaboration as it is defined in this Section
16
or with such collaboration as is available.
17

(h)
Any physician who collaborates with a physician
18
assistant providing medical care in response to such an
19
emergency or state or local disaster shall not be required to
20
meet the requirements set forth in this Section for a
21
collaborating physician.
22
(Source: P.A. 103-65, eff. 1-1-24
.)

23

(225 ILCS 95/7.5)
24

(Section scheduled to be repealed on January 1, 2028)
25

Sec. 7.5.
Written collaborative agreements
; prescriptive

SB0271
- 10 -
LRB104 03116 AAS 13137 b
1
authority
.
2

(a) A written collaborative agreement is required for all
3
physician assistants to practice in the State, except as
4
provided in
Sections

Section
7.7
and 7.9
of this Act.
When a
5
written collaborative agreement is required under this Act,
6
the following shall apply:

7

(1) A written collaborative agreement shall describe
8

the working relationship of the physician assistant with
9

the collaborating physician and shall describe the
10

categories of care, treatment, or procedures to be
11

provided by the physician assistant.
The written
12

collaborative agreement shall promote the exercise of
13

professional judgment by the physician assistant
14

commensurate with his or her education and experience. The
15

services to be provided by the physician assistant shall
16

be services that the collaborating physician is authorized
17

to and generally provides to his or her patients in the
18

normal course of his or her clinical medical practice. The
19

written collaborative agreement need not describe the
20

exact steps that a physician assistant must take with
21

respect to each specific condition, disease, or symptom
22

but must specify which authorized procedures require the
23

presence of the collaborating physician as the procedures
24

are being performed.
The relationship under a written
25

collaborative agreement shall not be construed to require
26

the personal presence of a physician at the place where

SB0271
- 11 -
LRB104 03116 AAS 13137 b
1

services are rendered. Methods of communication shall be
2

available for consultation with the collaborating
3

physician in person or by telecommunications or electronic
4

communications as set forth in the written collaborative
5

agreement.
For the purposes of this Act, "generally
6

provides to his or her patients in the normal course of his
7

or her clinical medical practice" means services, not
8

specific tasks or duties, the collaborating physician
9

routinely provides individually or through delegation to
10

other persons so that the physician has the experience and
11

ability to collaborate and provide consultation.

12

(2)
(Blank).

The written collaborative agreement shall
13

be adequate if a physician does each of the following:
14

(A) Participates in the joint formulation and
15

joint approval of orders or guidelines with the
16

physician assistant and he or she periodically reviews
17

such orders and the services provided patients under
18

such orders in accordance with accepted standards of
19

medical practice and physician assistant practice.
20

(B) Provides consultation at least once a month.

21

(3) A copy of the signed, written collaborative
22

agreement must be available to the Department upon request
23

from both the physician assistant and the collaborating
24

physician
.
25

(4) A physician assistant shall inform each
26

collaborating physician of all written collaborative

SB0271
- 12 -
LRB104 03116 AAS 13137 b
1

agreements he or she has signed and provide a copy of these
2

to any collaborating physician upon request.
3

(b)
To prescribe Schedule II, III, IV, or V controlled
4
substances under this Section, a physician assistant must
5
obtain a mid-level practitioner controlled substances license.

6
A collaborating physician may, but is not required to,
7
delegate prescriptive authority to a physician assistant as
8
part of a written collaborative agreement. This authority may,
9
but is not required to, include prescription of, selection of,
10
orders for, administration of, storage of, acceptance of
11
samples of, and dispensing medical devices, over-the-counter
12
medications, legend drugs, medical gases, and controlled
13
substances categorized as Schedule II through V controlled
14
substances, as defined in Article II of the Illinois
15
Controlled Substances Act, and other preparations, including,
16
but not limited to, botanical and herbal remedies. The
17
collaborating physician must have a valid, current Illinois
18
controlled substance license and federal registration with the
19
Drug Enforcement Administration to delegate the authority to
20
prescribe controlled substances.

21

(1) To prescribe Schedule II, III, IV, or V controlled
22

substances under this Section, a physician assistant must
23

obtain a mid-level practitioner controlled substances
24

license. Medication orders issued by a physician assistant
25

shall be reviewed periodically by the collaborating
26

physician.

SB0271
- 13 -
LRB104 03116 AAS 13137 b
1

(2) The collaborating physician shall file with the
2

Department notice of delegation of prescriptive authority
3

to a physician assistant and termination of delegation,
4

specifying the authority delegated or terminated. Upon
5

receipt of this notice delegating authority to prescribe
6

controlled substances, the physician assistant shall be
7

eligible to register for a mid-level practitioner
8

controlled substances license under Section 303.05 of the
9

Illinois Controlled Substances Act. Nothing in this Act
10

shall be construed to limit the delegation of tasks or
11

duties by the collaborating physician to a nurse or other
12

appropriately trained persons in accordance with Section
13

54.2 of the Medical Practice Act of 1987.
14

(3) In addition to the requirements of this subsection
15

(b), a collaborating physician may, but is not required
16

to, delegate authority to a physician assistant to
17

prescribe Schedule II controlled substances, if all of the
18

following conditions apply:
19

(A) Specific Schedule II controlled substances by
20

oral dosage or topical or transdermal application may
21

be delegated, provided that the delegated Schedule II
22

controlled substances are routinely prescribed by the
23

collaborating physician. This delegation must identify
24

the specific Schedule II controlled substances by
25

either brand name or generic name. Schedule II
26

controlled substances to be delivered by injection or

SB0271
- 14 -
LRB104 03116 AAS 13137 b
1

other route of administration may not be delegated.
2

(B) (Blank).
3

(C) Any prescription must be limited to no more
4

than a 30-day supply, with any continuation authorized
5

only after prior approval of the collaborating
6

physician.
7

(D) The physician assistant must discuss the
8

condition of any patients for whom a controlled
9

substance is prescribed monthly with the collaborating
10

physician.
11

(E) The physician assistant meets the education
12

requirements of Section 303.05 of the Illinois
13

Controlled Substances Act.

14

(c) Nothing in this Act shall be construed to limit the
15
delegation of tasks or duties by a physician to a licensed
16
practical nurse, a registered professional nurse, or other
17
persons. Nothing in this Act shall be construed to limit the
18
method of delegation that may be authorized by any means,
19
including, but not limited to, oral, written, electronic,
20
standing orders, protocols, guidelines, or verbal orders.
21
Nothing in this Act shall be construed to authorize a
22
physician assistant to provide health care services required
23
by law or rule to be performed by a physician. Nothing in this
24
Act shall be construed to authorize the delegation or
25
performance of operative surgery. Nothing in this Section
26
shall be construed to preclude a physician assistant from

SB0271
- 15 -
LRB104 03116 AAS 13137 b
1
assisting in surgery.
2

(c-5) Nothing in this Section shall be construed to apply
3
to any medication authority, including Schedule II controlled
4
substances of a licensed physician assistant for care provided
5
in a hospital, hospital affiliate, federally qualified health
6
center, or ambulatory surgical treatment center pursuant to
7
Section 7.7 of this Act
, or to a physician assistant
8
satisfying the requirements of Section 7.9 of this Act
.
9

(d) (Blank).
10

(e) Nothing in this Section shall be construed to prohibit
11
generic substitution.
12

(f) Delegation of prescriptive authority by a physician is
13
not required under this Section.
14
(Source: P.A. 102-558, eff. 8-20-21; 103-65, eff. 1-1-24;
15
103-605, eff. 7-1-24.)

16

(225 ILCS 95/7.7)
17

(Section scheduled to be repealed on January 1, 2028)
18

Sec. 7.7.
Physician assistants in hospitals, hospital
19
affiliates, federally qualified health centers, or ambulatory
20
surgical treatment centers.
21

(a) A physician assistant may provide services in a
22
hospital as defined in the Hospital Licensing Act, a hospital
23
affiliate as defined in the University of Illinois Hospital
24
Act, a federally qualified health center, or a licensed
25
ambulatory surgical treatment center as defined in the

SB0271
- 16 -
LRB104 03116 AAS 13137 b
1
Ambulatory Surgical Treatment Center Act without a written
2
collaborative agreement pursuant to Section 7.5 of this Act
3
only in accordance with this Section. A physician assistant
4
must possess clinical privileges recommended by (i) the
5
hospital medical staff and granted by the hospital, (ii) the
6
physician committee and federally qualified health center, or
7
(iii) the consulting medical staff committee and ambulatory
8
surgical treatment center in order to provide services. The
9
medical staff, physician committee, or consulting medical
10
staff committee shall periodically review the services of
11
physician assistants granted clinical privileges, including
12
any care provided in a hospital affiliate or federally
13
qualified health center.
A physician assistant practicing
14
under this Section may prescribe, select, order, and
15
administer medications, including controlled substances.

16
Authority may also be granted when recommended by the hospital
17
medical staff and granted by the hospital, recommended by the
18
physician committee and granted by the federally qualified
19
health center, or recommended by the consulting medical staff
20
committee and ambulatory surgical treatment center to
21
individual physician assistants to select, order, and
22
administer medications, including controlled substances, to
23
provide delineated care.
In a hospital, hospital affiliate,
24
federally qualified health center, or ambulatory surgical
25
treatment center, the attending physician shall determine a
26
physician assistant's role in providing care for his or her

SB0271
- 17 -
LRB104 03116 AAS 13137 b
1
patients, except as otherwise provided in the medical staff
2
bylaws or consulting committee policies.
3

(a-5) Physician assistants practicing in a hospital
4
affiliate or a federally qualified health center may
be, but
5
are not required to be, granted authority to
prescribe
6
Schedule II through V controlled substances
when such
7
authority is recommended by the appropriate physician
8
committee of the hospital affiliate and granted by the
9
hospital affiliate or recommended by the physician committee
10
of the federally qualified health center and granted by the
11
federally qualified health center
. This authority may
, but is
12
not required to,
include prescription of, selection of, orders
13
for, administration of, storage of, acceptance of samples of,
14
and dispensing over-the-counter medications, legend drugs,
15
medical gases, and controlled substances categorized as
16
Schedule II through V controlled substances, as defined in
17
Article II of the Illinois Controlled Substances Act, and
18
other preparations, including, but not limited to, botanical
19
and herbal remedies.
20

To prescribe controlled substances under this subsection
21
(a-5), a physician assistant must obtain a mid-level
22
practitioner controlled substance license.
Medication orders
23
shall be reviewed periodically by the appropriate hospital
24
affiliate physicians committee or its physician designee or by
25
the physician committee of a federally qualified health
26
center.

SB0271
- 18 -
LRB104 03116 AAS 13137 b
1

The hospital affiliate or federally qualified health
2
center shall file with the Department notice of a grant of
3
prescriptive authority consistent with this subsection (a-5)
4
and termination of such a grant of authority in accordance
5
with rules of the Department. Upon receipt of this notice of
6
grant of authority to prescribe any Schedule II through V
7
controlled substances, the licensed physician assistant may
8
register for a mid-level practitioner controlled substance
9
license under Section 303.05 of the Illinois Controlled
10
Substances Act.
11

In addition, a hospital affiliate or a federally qualified
12
health center may, but is not required to, grant authority to a
13
physician assistant to prescribe any Schedule II controlled
14
substances if all of the following conditions apply:
15

(1) specific Schedule II controlled substances by oral
16

dosage or topical or transdermal application may be
17

designated, provided that the designated Schedule II
18

controlled substances are routinely prescribed by
19

physician assistants in their area of certification; this
20

grant of authority must identify the specific Schedule II
21

controlled substances by either brand name or generic
22

name; authority to prescribe or dispense Schedule II
23

controlled substances to be delivered by injection or
24

other route of administration may not be granted;
25

(2) any grant of authority must be controlled
26

substances limited to the practice of the physician

SB0271
- 19 -
LRB104 03116 AAS 13137 b
1

assistant;
2

(3) any prescription must be limited to no more than a
3

30-day supply;
4

(4) the physician assistant must discuss the condition
5

of any patients for whom a controlled substance is
6

prescribed monthly with the appropriate physician
7

committee of the hospital affiliate or its physician
8

designee, or the physician committee of a federally
9

qualified health center; and
10

(5) the physician assistant must meet the education
11

requirements of Section 303.05 of the Illinois Controlled
12

Substances Act.

13

(b) A physician assistant
granted authority to order
14
medications including controlled substances
may complete
15
discharge prescriptions provided the prescription is in the
16
name of the physician assistant
and the attending or
17
discharging physician
.
18

(c) Physician assistants practicing in a hospital,
19
hospital affiliate, federally qualified health center, or an
20
ambulatory surgical treatment center are not required to
21
obtain a mid-level controlled substance license to order
22
controlled substances under Section 303.05 of the Illinois
23
Controlled Substances Act.
24

(d) Delegation of prescriptive authority by a physician is
25
not required under this Section.

26
(Source: P.A. 103-65, eff. 1-1-24
.)

SB0271
- 20 -
LRB104 03116 AAS 13137 b
1

(225 ILCS 95/7.8 new)
2

Sec. 7.8.
Prescriptive authority.
A physician assistant
3
may prescribe, dispense, order, administer, and procure drugs
4
and medical devices without delegation of authority by a
5
physician. The prescriptive authority may include prescribing
6
Schedule II, III, IV, and V controlled substances. To
7
prescribe Schedule II, III, IV, or V controlled substances
8
under this Act, a physician assistant must obtain a mid-level
9
practitioner controlled substances license. When a written
10
collaborative agreement is required under this Act, delegation
11
of prescriptive authority by a physician is not required.

12

(225 ILCS 95/7.9 new)
13

Sec. 7.9.
Optimal practice.
14

(a) A physician assistant may practice without a written
15
collaborative agreement as described in this Section.
16

(b) A physician assistant who files with the Department a
17
notarized attestation of completion of at least 250 hours of
18
continuing education or training and at least 2,000 hours of
19
clinical experience after first attaining national
20
certification shall not require a written collaborative
21
agreement to practice. Documentation of successful completion
22
shall be provided to the Department upon request.
23

(c) The scope of practice of a physician assistant with
24
optimal practice includes:

SB0271
- 21 -
LRB104 03116 AAS 13137 b
1

(1) all matters defined as physician assistant
2

practice;
3

(2) practicing without a written collaborative
4

agreement in all practice settings consistent with this
5

Act;
6

(3) authority to prescribe both legend drugs and
7

Schedule II through V controlled substances, including
8

prescription of, selection of, orders for, administration
9

of, storage of, acceptance of, samples of, and dispensing
10

over-the-counter medications, legend drugs, and controlled
11

substances categorized as Schedule II through V controlled
12

substances, as defined in Article II of the Illinois
13

Controlled Substances Act, and other preparations,
14

including, but not limited to, botanical and herbal
15

remedies; and
16

(4) authority to obtain an Illinois controlled
17

substance license and a federal Drug Enforcement
18

Administration number.
19

The scope of practice of a physician assistant does not
20
include operative surgery. Nothing in this Section shall be
21
construed to preclude a physician assistant from assisting in
22
surgery or performing other procedures as privileged by the
23
physician assistant's employer.
24

(d) The Department may adopt rules necessary to administer
25
this Section, including, but not limited to, requiring the
26
completion of forms and the payment of fees.

SB0271
- 22 -
LRB104 03116 AAS 13137 b
1

(e) Nothing in this Section shall be construed to prohibit
2
a physician assistant's employer from requiring a physician
3
assistant who satisfies the qualifications of subsection (b)
4
to practice with a written collaborative agreement.
5

(f) Nothing in this Act shall be construed to authorize a
6
physician assistant with optimal practice authority to provide
7
health care services required by law or rule to be performed by
8
a physician.

9

(225 ILCS 95/20)

(from Ch. 111, par. 4620)
10

(Section scheduled to be repealed on January 1, 2028)
11

Sec. 20.
Limitations.

12

(a)
No corporation, which stated purpose includes, or
13
which practices, or which holds itself out as available to
14
practice as a physician assistant or to practice any of the
15
functions described in Section 4 of this Act, shall be issued a
16
license by the Department, nor shall the Secretary of State
17
approve or accept articles of incorporation for such a
18
corporation.
19

(b) Pursuant to subparagraph (a) of paragraph (2) of
20
Section 3.6 of the Professional Service Corporation Act and
21
Section 2 of the Medical Corporation Act, a person licensed
22
under this Act may not own a corporation for the purposes of
23
practicing medicine.
24

(c) Pursuant to paragraph (2) of subsection (a) of Section
25
13 of the Professional Limited Liability Company Act, a person

SB0271
- 23 -
LRB104 03116 AAS 13137 b
1
licensed under this Act may not own a professional limited
2
liability company for the purposes of practicing medicine.
3
(Source: P.A. 85-981
.)

4

(225 ILCS 95/21)

(from Ch. 111, par. 4621)
5

(Section scheduled to be repealed on January 1, 2028)
6

Sec. 21.
Grounds for disciplinary action.
7

(a) The Department may refuse to issue or to renew, or may
8
revoke, suspend, place on probation, reprimand, or take other
9
disciplinary or non-disciplinary action with regard to any
10
license issued under this Act as the Department may deem
11
proper, including the issuance of fines not to exceed $10,000
12
for each violation, for any one or combination of the
13
following causes:
14

(1) Material misstatement in furnishing information to
15

the Department.
16

(2) Violations of this Act, or the rules adopted under
17

this Act.
18

(3) Conviction by plea of guilty or nolo contendere,
19

finding of guilt, jury verdict, or entry of judgment or
20

sentencing, including, but not limited to, convictions,
21

preceding sentences of supervision, conditional discharge,
22

or first offender probation, under the laws of any
23

jurisdiction of the United States that is: (i) a felony;
24

or (ii) a misdemeanor, an essential element of which is
25

dishonesty, or that is directly related to the practice of

SB0271
- 24 -
LRB104 03116 AAS 13137 b
1

the profession.
2

(4) Making any misrepresentation for the purpose of
3

obtaining licenses.
4

(5) Professional incompetence.
5

(6) Aiding or assisting another person in violating
6

any provision of this Act or its rules.
7

(7) Failing, within 60 days, to provide information in
8

response to a written request made by the Department.
9

(8) Engaging in dishonorable, unethical, or
10

unprofessional conduct, as defined by rule, of a character
11

likely to deceive, defraud, or harm the public.
12

(9) Habitual or excessive use or addiction to alcohol,
13

narcotics, stimulants, or any other chemical agent or drug
14

that results in a physician assistant's inability to
15

practice with reasonable judgment, skill, or safety.
16

(10) Discipline by another U.S. jurisdiction or
17

foreign nation, if at least one of the grounds for
18

discipline is the same or substantially equivalent to
19

those set forth in this Section.
20

(11) Directly or indirectly giving to or receiving
21

from any person, firm, corporation, partnership, or
22

association any fee, commission, rebate or other form of
23

compensation for any professional services not actually or
24

personally rendered. Nothing in this paragraph (11)
25

affects any bona fide independent contractor or employment
26

arrangements, which may include provisions for

SB0271
- 25 -
LRB104 03116 AAS 13137 b
1

compensation, health insurance, pension, or other
2

employment benefits, with persons or entities authorized
3

under this Act for the provision of services within the
4

scope of the licensee's practice under this Act.
5

(12) A finding by the Board that the licensee, after
6

having his or her license placed on probationary status,
7

has violated the terms of probation.
8

(13) Abandonment of a patient.
9

(14) Willfully making or filing false records or
10

reports in his or her practice, including
,
but not limited
11

to
,
false records filed with State agencies or
12

departments.
13

(15) Willfully failing to report an instance of
14

suspected child abuse or neglect as required by the Abused
15

and Neglected Child Reporting Act.
16

(16) Physical illness, or mental illness or impairment
17

that results in the inability to practice the profession
18

with reasonable judgment, skill, or safety, including, but
19

not limited to, deterioration through the aging process or
20

loss of motor skill.
21

(17) Being named as a perpetrator in an indicated
22

report by the Department of Children and Family Services
23

under the Abused and Neglected Child Reporting Act, and
24

upon proof by clear and convincing evidence that the
25

licensee has caused a child to be an abused child or
26

neglected child as defined in the Abused and Neglected

SB0271
- 26 -
LRB104 03116 AAS 13137 b
1

Child Reporting Act.
2

(18) (Blank).
3

(19) Gross negligence resulting in permanent injury or
4

death of a patient.
5

(20) Employment of fraud, deception or any unlawful
6

means in applying for or securing a license as a physician
7

assistant.
8

(21) Exceeding the authority delegated to him or her
9

by his or her collaborating physician in a written
10

collaborative agreement
, when the agreement is required
11

under this Act
.
12

(22) Immoral conduct in the commission of any act,
13

such as sexual abuse, sexual misconduct, or sexual
14

exploitation related to the licensee's practice.
15

(23) Violation of the Health Care Worker Self-Referral
16

Act.
17

(24) Practicing under a false or assumed name, except
18

as provided by law.
19

(25) Making a false or misleading statement regarding
20

his or her skill or the efficacy or value of the medicine,
21

treatment, or remedy prescribed by him or her in the
22

course of treatment.
23

(26) Allowing another person to use his or her license
24

to practice.
25

(27) Prescribing, selling, administering,
26

distributing, giving, or self-administering a drug

SB0271
- 27 -
LRB104 03116 AAS 13137 b
1

classified as a controlled substance for other than
2

medically accepted therapeutic purposes.
3

(28) Promotion of the sale of drugs, devices,
4

appliances, or goods provided for a patient in a manner to
5

exploit the patient for financial gain.
6

(29) A pattern of practice or other behavior that
7

demonstrates incapacity or incompetence to practice under
8

this Act.
9

(30) Violating State or federal laws or regulations
10

relating to controlled substances or other legend drugs or
11

ephedra as defined in the Ephedra Prohibition Act.
12

(31)
(Blank).

Exceeding the prescriptive authority
13

delegated by the collaborating physician or violating the
14

written collaborative agreement delegating that authority.
15

(32)
(Blank).

Practicing without providing to the
16

Department a notice of collaboration or delegation of
17

prescriptive authority.
18

(33) Failure to establish and maintain records of
19

patient care and treatment as required by law.
20

(34) Attempting to subvert or cheat on the examination
21

of the National Commission on Certification of Physician
22

Assistants or its successor agency.
23

(35) Willfully or negligently violating the
24

confidentiality between physician assistant and patient,
25

except as required by law.
26

(36) Willfully failing to report an instance of

SB0271
- 28 -
LRB104 03116 AAS 13137 b
1

suspected abuse, neglect, financial exploitation, or
2

self-neglect of an eligible adult as defined in and
3

required by the Adult Protective Services Act.
4

(37) Being named as an abuser in a verified report by
5

the Department on Aging under the Adult Protective
6

Services Act and upon proof by clear and convincing
7

evidence that the licensee abused, neglected, or
8

financially exploited an eligible adult as defined in the
9

Adult Protective Services Act.
10

(38) Failure to report to the Department an adverse
11

final action taken against him or her by another licensing
12

jurisdiction of the United States or a foreign state or
13

country, a peer review body, a health care institution, a
14

professional society or association, a governmental
15

agency, a law enforcement agency, or a court acts or
16

conduct similar to acts or conduct that would constitute
17

grounds for action under this Section.
18

(39) Failure to provide copies of records of patient
19

care or treatment, except as required by law.
20

(40)
(Blank).

Entering into an excessive number of
21

written collaborative agreements with licensed physicians
22

resulting in an inability to adequately collaborate.
23

(41)
(Blank).

Repeated failure to adequately
24

collaborate with a collaborating physician.
25

(42) Violating the Compassionate Use of Medical
26

Cannabis Program Act.

SB0271
- 29 -
LRB104 03116 AAS 13137 b
1

(b) The Department may, without a hearing, refuse to issue
2
or renew or may suspend the license of any person who fails to
3
file a return, or to pay the tax, penalty or interest shown in
4
a filed return, or to pay any final assessment of the tax,
5
penalty, or interest as required by any tax Act administered
6
by the Illinois Department of Revenue, until such time as the
7
requirements of any such tax Act are satisfied.
8

(b-5) The Department shall not revoke, suspend, summarily
9
suspend, place on prohibition, reprimand, refuse to issue or
10
renew, or take any other disciplinary or non-disciplinary
11
action against the license or permit issued under this Act to
12
practice as a physician assistant based solely upon the
13
physician assistant providing, authorizing, recommending,
14
aiding, assisting, referring for, or otherwise participating
15
in any health care service, so long as the care was not
16
unlawful under the laws of this State, regardless of whether
17
the patient was a resident of this State or another state.
18

(b-10) The Department shall not revoke, suspend, summarily
19
suspend, place on prohibition, reprimand, refuse to issue or
20
renew, or take any other disciplinary or non-disciplinary
21
action against the license or permit issued under this Act to
22
practice as a physician assistant based upon the physician
23
assistant's license being revoked or suspended, or the
24
physician assistant being otherwise disciplined by any other
25
state, if that revocation, suspension, or other form of
26
discipline was based solely on the physician assistant

SB0271
- 30 -
LRB104 03116 AAS 13137 b
1
violating another state's laws prohibiting the provision of,
2
authorization of, recommendation of, aiding or assisting in,
3
referring for, or participation in any health care service if
4
that health care service as provided would not have been
5
unlawful under the laws of this State and is consistent with
6
the standards of conduct for a physician assistant practicing
7
in Illinois.
8

(b-15) The conduct specified in subsections (b-5) and
9
(b-10) shall not constitute grounds for suspension under
10
Section 22.13.
11

(b-20) An applicant seeking licensure, certification, or
12
authorization pursuant to this Act who has been subject to
13
disciplinary action by a duly authorized professional
14
disciplinary agency of another jurisdiction solely on the
15
basis of having provided, authorized, recommended, aided,
16
assisted, referred for, or otherwise participated in health
17
care shall not be denied such licensure, certification, or
18
authorization, unless the Department determines that such
19
action would have constituted professional misconduct in this
20
State; however, nothing in this Section shall be construed as
21
prohibiting the Department from evaluating the conduct of such
22
applicant and making a determination regarding the licensure,
23
certification, or authorization to practice a profession under
24
this Act.
25

(c) The determination by a circuit court that a licensee
26
is subject to involuntary admission or judicial admission as

SB0271
- 31 -
LRB104 03116 AAS 13137 b
1
provided in the Mental Health and Developmental Disabilities
2
Code operates as an automatic suspension. The suspension will
3
end only upon a finding by a court that the patient is no
4
longer subject to involuntary admission or judicial admission
5
and issues an order so finding and discharging the patient,
6
and upon the recommendation of the Board to the Secretary that
7
the licensee be allowed to resume his or her practice.
8

(d) In enforcing this Section, the Department upon a
9
showing of a possible violation may compel an individual
10
licensed to practice under this Act, or who has applied for
11
licensure under this Act, to submit to a mental or physical
12
examination, or both, which may include a substance abuse or
13
sexual offender evaluation, as required by and at the expense
14
of the Department.
15

The Department shall specifically designate the examining
16
physician licensed to practice medicine in all of its branches
17
or, if applicable, the multidisciplinary team involved in
18
providing the mental or physical examination or both. The
19
multidisciplinary team shall be led by a physician licensed to
20
practice medicine in all of its branches and may consist of one
21
or more or a combination of physicians licensed to practice
22
medicine in all of its branches, licensed clinical
23
psychologists, licensed clinical social workers, licensed
24
clinical professional counselors, and other professional and
25
administrative staff. Any examining physician or member of the
26
multidisciplinary team may require any person ordered to

SB0271
- 32 -
LRB104 03116 AAS 13137 b
1
submit to an examination pursuant to this Section to submit to
2
any additional supplemental testing deemed necessary to
3
complete any examination or evaluation process, including, but
4
not limited to, blood testing, urinalysis, psychological
5
testing, or neuropsychological testing.
6

The Department may order the examining physician or any
7
member of the multidisciplinary team to provide to the
8
Department any and all records, including business records,
9
that relate to the examination and evaluation, including any
10
supplemental testing performed.
11

The Department may order the examining physician or any
12
member of the multidisciplinary team to present testimony
13
concerning the mental or physical examination of the licensee
14
or applicant. No information, report, record, or other
15
documents in any way related to the examination shall be
16
excluded by reason of any common law or statutory privilege
17
relating to communications between the licensee or applicant
18
and the examining physician or any member of the
19
multidisciplinary team. No authorization is necessary from the
20
licensee or applicant ordered to undergo an examination for
21
the examining physician or any member of the multidisciplinary
22
team to provide information, reports, records, or other
23
documents or to provide any testimony regarding the
24
examination and evaluation.
25

The individual to be examined may have, at his or her own
26
expense, another physician of his or her choice present during

SB0271
- 33 -
LRB104 03116 AAS 13137 b
1
all aspects of this examination. However, that physician shall
2
be present only to observe and may not interfere in any way
3
with the examination.
4

Failure of an individual to submit to a mental or physical
5
examination, when ordered, shall result in an automatic
6
suspension of his or her license until the individual submits
7
to the examination.
8

If the Department finds an individual unable to practice
9
because of the reasons set forth in this Section, the
10
Department may require that individual to submit to care,
11
counseling, or treatment by physicians approved or designated
12
by the Department, as a condition, term, or restriction for
13
continued, reinstated, or renewed licensure to practice; or,
14
in lieu of care, counseling, or treatment, the Department may
15
file a complaint to immediately suspend, revoke, or otherwise
16
discipline the license of the individual. An individual whose
17
license was granted, continued, reinstated, renewed,
18
disciplined, or supervised subject to such terms, conditions,
19
or restrictions, and who fails to comply with such terms,
20
conditions, or restrictions, shall be referred to the
21
Secretary for a determination as to whether the individual
22
shall have his or her license suspended immediately, pending a
23
hearing by the Department.
24

In instances in which the Secretary immediately suspends a
25
person's license under this Section, a hearing on that
26
person's license must be convened by the Department within 30

SB0271
- 34 -
LRB104 03116 AAS 13137 b
1
days after the suspension and completed without appreciable
2
delay. The Department shall have the authority to review the
3
subject individual's record of treatment and counseling
4
regarding the impairment to the extent permitted by applicable
5
federal statutes and regulations safeguarding the
6
confidentiality of medical records.
7

An individual licensed under this Act and affected under
8
this Section shall be afforded an opportunity to demonstrate
9
to the Department that he or she can resume practice in
10
compliance with acceptable and prevailing standards under the
11
provisions of his or her license.
12

(e) An individual or organization acting in good faith,
13
and not in a willful and wanton manner, in complying with this
14
Section by providing a report or other information to the
15
Board, by assisting in the investigation or preparation of a
16
report or information, by participating in proceedings of the
17
Board, or by serving as a member of the Board, shall not be
18
subject to criminal prosecution or civil damages as a result
19
of such actions.
20

(f) Members of the Board shall be indemnified by the State
21
for any actions occurring within the scope of services on the
22
Board, done in good faith and not willful and wanton in nature.
23
The Attorney General shall defend all such actions unless he
24
or she determines either that there would be a conflict of
25
interest in such representation or that the actions complained
26
of were not in good faith or were willful and wanton.

SB0271
- 35 -
LRB104 03116 AAS 13137 b
1

If the Attorney General declines representation, the
2
member has the right to employ counsel of his or her choice,
3
whose fees shall be provided by the State, after approval by
4
the Attorney General, unless there is a determination by a
5
court that the member's actions were not in good faith or were
6
willful and wanton.
7

The member must notify the Attorney General within 7 days
8
after receipt of notice of the initiation of any action
9
involving services of the Board. Failure to so notify the
10
Attorney General constitutes an absolute waiver of the right
11
to a defense and indemnification.
12

The Attorney General shall determine, within 7 days after
13
receiving such notice, whether he or she will undertake to
14
represent the member.
15

(g) The Department may adopt rules to implement the
16
changes made by this amendatory Act of the 102nd General
17
Assembly.
18
(Source: P.A. 101-363, eff. 8-9-19; 102-558, eff. 8-20-21;
19
102-1117, eff. 1-13-23.)

20

Section 10.
The Illinois Controlled Substances Act is
21
amended by changing Sections 102 and 303.05 as follows:

22

(720 ILCS 570/102)

(from Ch. 56 1/2, par. 1102)
23

Sec. 102.
Definitions.
As used in this Act, unless the
24
context otherwise requires:

SB0271
- 36 -
LRB104 03116 AAS 13137 b
1

(a) "Person with a substance use disorder" means any
2
person who has a substance use disorder diagnosis defined as a
3
spectrum of persistent and recurring problematic behavior that
4
encompasses 10 separate classes of drugs: alcohol; caffeine;
5
cannabis; hallucinogens; inhalants; opioids; sedatives,
6
hypnotics and anxiolytics; stimulants; and tobacco; and other
7
unknown substances leading to clinically significant
8
impairment or distress.
9

(b) "Administer" means the direct application of a
10
controlled substance, whether by injection, inhalation,
11
ingestion, or any other means, to the body of a patient,
12
research subject, or animal (as defined by the Humane
13
Euthanasia in Animal Shelters Act) by:
14

(1) a practitioner (or, in his or her presence, by his
15

or her authorized agent),
16

(2) the patient or research subject pursuant to an
17

order, or
18

(3) a euthanasia technician as defined by the Humane
19

Euthanasia in Animal Shelters Act.
20

(c) "Agent" means an authorized person who acts on behalf
21
of or at the direction of a manufacturer, distributor,
22
dispenser, prescriber, or practitioner. It does not include a
23
common or contract carrier, public warehouseman or employee of
24
the carrier or warehouseman.
25

(c-1) "Anabolic Steroids" means any drug or hormonal
26
substance, chemically and pharmacologically related to

SB0271
- 37 -
LRB104 03116 AAS 13137 b
1
testosterone (other than estrogens, progestins,
2
corticosteroids, and dehydroepiandrosterone), and includes:
3

(i) 3[beta],17-dihydroxy-5a-androstane,
4

(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
5

(iii) 5[alpha]-androstan-3,17-dione,
6

(iv) 1-androstenediol (3[beta],
7

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
8

(v) 1-androstenediol (3[alpha],
9

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
10

(vi) 4-androstenediol
11

(3[beta],17[beta]-dihydroxy-androst-4-ene),
12

(vii) 5-androstenediol
13

(3[beta],17[beta]-dihydroxy-androst-5-ene),
14

(viii) 1-androstenedione
15

([5alpha]-androst-1-en-3,17-dione),
16

(ix) 4-androstenedione
17

(androst-4-en-3,17-dione),
18

(x) 5-androstenedione
19

(androst-5-en-3,17-dione),
20

(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
21

hydroxyandrost-4-en-3-one),
22

(xii) boldenone (17[beta]-hydroxyandrost-
23

1,4,-diene-3-one),
24

(xiii) boldione (androsta-1,4-
25

diene-3,17-dione),
26

(xiv) calusterone (7[beta],17[alpha]-dimethyl-17

SB0271
- 38 -
LRB104 03116 AAS 13137 b
1

[beta]-hydroxyandrost-4-en-3-one),
2

(xv) clostebol (4-chloro-17[beta]-
3

hydroxyandrost-4-en-3-one),
4

(xvi) dehydrochloromethyltestosterone (4-chloro-
5

17[beta]-hydroxy-17[alpha]-methyl-
6

androst-1,4-dien-3-one),
7

(xvii) desoxymethyltestosterone
8

(17[alpha]-methyl-5[alpha]
9

-androst-2-en-17[beta]-ol)(a.k.a., madol),
10

(xviii) [delta]1-dihydrotestosterone (a.k.a.
11

'1-testosterone') (17[beta]-hydroxy-
12

5[alpha]-androst-1-en-3-one),
13

(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
14

androstan-3-one),
15

(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
16

5[alpha]-androstan-3-one),
17

(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
18

hydroxyestr-4-ene),
19

(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
20

1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
21

(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
22

17[beta]-dihydroxyandrost-1,4-dien-3-one),
23

(xxiv) furazabol (17[alpha]-methyl-17[beta]-
24

hydroxyandrostano[2,3-c]-furazan),
25

(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
26

(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-

SB0271
- 39 -
LRB104 03116 AAS 13137 b
1

androst-4-en-3-one),
2

(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
3

dihydroxy-estr-4-en-3-one),
4

(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
5

hydroxy-5-androstan-3-one),
6

(xxix) mesterolone (1amethyl-17[beta]-hydroxy-
7

[5a]-androstan-3-one),
8

(xxx) methandienone (17[alpha]-methyl-17[beta]-
9

hydroxyandrost-1,4-dien-3-one),
10

(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
11

dihydroxyandrost-5-ene),
12

(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
13

5[alpha]-androst-1-en-3-one),
14

(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
15

dihydroxy-5a-androstane,
16

(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
17

-5a-androstane,
18

(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
19

dihydroxyandrost-4-ene),
20

(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
21

methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
22

(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
23

hydroxyestra-4,9(10)-dien-3-one),
24

(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
25

hydroxyestra-4,9-11-trien-3-one),
26

(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-

SB0271
- 40 -
LRB104 03116 AAS 13137 b
1

hydroxyandrost-4-en-3-one),
2

(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
3

hydroxyestr-4-en-3-one),
4

(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
5

(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
6

androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
7

1-testosterone'),
8

(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
9

(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
10

dihydroxyestr-4-ene),
11

(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
12

dihydroxyestr-4-ene),
13

(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
14

dihydroxyestr-5-ene),
15

(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
16

dihydroxyestr-5-ene),
17

(xlvii) 19-nor-4,9(10)-androstadienedione
18

(estra-4,9(10)-diene-3,17-dione),
19

(xlviii) 19-nor-4-androstenedione (estr-4-
20

en-3,17-dione),
21

(xlix) 19-nor-5-androstenedione (estr-5-
22

en-3,17-dione),
23

(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
24

hydroxygon-4-en-3-one),
25

(li) norclostebol (4-chloro-17[beta]-
26

hydroxyestr-4-en-3-one),

SB0271
- 41 -
LRB104 03116 AAS 13137 b
1

(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
2

hydroxyestr-4-en-3-one),
3

(liii) normethandrolone (17[alpha]-methyl-17[beta]-
4

hydroxyestr-4-en-3-one),
5

(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
6

2-oxa-5[alpha]-androstan-3-one),
7

(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
8

dihydroxyandrost-4-en-3-one),
9

(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
10

17[beta]-hydroxy-(5[alpha]-androstan-3-one),
11

(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
12

(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
13

(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
14

(5[alpha]-androst-1-en-3-one),
15

(lix) testolactone (13-hydroxy-3-oxo-13,17-
16

secoandrosta-1,4-dien-17-oic
17

acid lactone),
18

(lx) testosterone (17[beta]-hydroxyandrost-
19

4-en-3-one),
20

(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
21

diethyl-17[beta]-hydroxygon-
22

4,9,11-trien-3-one),
23

(lxii) trenbolone (17[beta]-hydroxyestr-4,9,
24

11-trien-3-one).
25

Any person who is otherwise lawfully in possession of an
26
anabolic steroid, or who otherwise lawfully manufactures,

SB0271
- 42 -
LRB104 03116 AAS 13137 b
1
distributes, dispenses, delivers, or possesses with intent to
2
deliver an anabolic steroid, which anabolic steroid is
3
expressly intended for and lawfully allowed to be administered
4
through implants to livestock or other nonhuman species, and
5
which is approved by the Secretary of Health and Human
6
Services for such administration, and which the person intends
7
to administer or have administered through such implants,
8
shall not be considered to be in unauthorized possession or to
9
unlawfully manufacture, distribute, dispense, deliver, or
10
possess with intent to deliver such anabolic steroid for
11
purposes of this Act.
12

(d) "Administration" means the Drug Enforcement
13
Administration, United States Department of Justice, or its
14
successor agency.
15

(d-5) "Clinical Director, Prescription Monitoring Program"
16
means a Department of Human Services administrative employee
17
licensed to either prescribe or dispense controlled substances
18
who shall run the clinical aspects of the Department of Human
19
Services Prescription Monitoring Program and its Prescription
20
Information Library.
21

(d-10) "Compounding" means the preparation and mixing of
22
components, excluding flavorings, (1) as the result of a
23
prescriber's prescription drug order or initiative based on
24
the prescriber-patient-pharmacist relationship in the course
25
of professional practice or (2) for the purpose of, or
26
incident to, research, teaching, or chemical analysis and not

SB0271
- 43 -
LRB104 03116 AAS 13137 b
1
for sale or dispensing. "Compounding" includes the preparation
2
of drugs or devices in anticipation of receiving prescription
3
drug orders based on routine, regularly observed dispensing
4
patterns. Commercially available products may be compounded
5
for dispensing to individual patients only if both of the
6
following conditions are met: (i) the commercial product is
7
not reasonably available from normal distribution channels in
8
a timely manner to meet the patient's needs and (ii) the
9
prescribing practitioner has requested that the drug be
10
compounded.
11

(e) "Control" means to add a drug or other substance, or
12
immediate precursor, to a Schedule whether by transfer from
13
another Schedule or otherwise.
14

(f) "Controlled Substance" means (i) a drug, substance,
15
immediate precursor, or synthetic drug in the Schedules of
16
Article II of this Act or (ii) a drug or other substance, or
17
immediate precursor, designated as a controlled substance by
18
the Department through administrative rule. The term does not
19
include distilled spirits, wine, malt beverages, or tobacco,
20
as those terms are defined or used in the Liquor Control Act of
21
1934 and the Tobacco Products Tax Act of 1995.
22

(f-5) "Controlled substance analog" means a substance:
23

(1) the chemical structure of which is substantially
24

similar to the chemical structure of a controlled
25

substance in Schedule I or II;
26

(2) which has a stimulant, depressant, or

SB0271
- 44 -
LRB104 03116 AAS 13137 b
1

hallucinogenic effect on the central nervous system that
2

is substantially similar to or greater than the stimulant,
3

depressant, or hallucinogenic effect on the central
4

nervous system of a controlled substance in Schedule I or
5

II; or
6

(3) with respect to a particular person, which such
7

person represents or intends to have a stimulant,
8

depressant, or hallucinogenic effect on the central
9

nervous system that is substantially similar to or greater
10

than the stimulant, depressant, or hallucinogenic effect
11

on the central nervous system of a controlled substance in
12

Schedule I or II.
13

(g) "Counterfeit substance" means a controlled substance,
14
which, or the container or labeling of which, without
15
authorization bears the trademark, trade name, or other
16
identifying mark, imprint, number or device, or any likeness
17
thereof, of a manufacturer, distributor, or dispenser other
18
than the person who in fact manufactured, distributed, or
19
dispensed the substance.
20

(h) "Deliver" or "delivery" means the actual, constructive
21
or attempted transfer of possession of a controlled substance,
22
with or without consideration, whether or not there is an
23
agency relationship. "Deliver" or "delivery" does not include
24
the donation of drugs to the extent permitted under the
25
Illinois Drug Reuse Opportunity Program Act.
26

(i) "Department" means the Illinois Department of Human

SB0271
- 45 -
LRB104 03116 AAS 13137 b
1
Services (as successor to the Department of Alcoholism and
2
Substance Abuse) or its successor agency.
3

(j) (Blank).
4

(k) "Department of Corrections" means the Department of
5
Corrections of the State of Illinois or its successor agency.
6

(l) "Department of Financial and Professional Regulation"
7
means the Department of Financial and Professional Regulation
8
of the State of Illinois or its successor agency.
9

(m) "Depressant" means any drug that (i) causes an overall
10
depression of central nervous system functions, (ii) causes
11
impaired consciousness and awareness, and (iii) can be
12
habit-forming or lead to a substance misuse or substance use
13
disorder, including, but not limited to, alcohol, cannabis and
14
its active principles and their analogs, benzodiazepines and
15
their analogs, barbiturates and their analogs, opioids
16
(natural and synthetic) and their analogs, and chloral hydrate
17
and similar sedative hypnotics.
18

(n) (Blank).
19

(o) "Director" means the Director of the Illinois State
20
Police or his or her designated agents.
21

(p) "Dispense" means to deliver a controlled substance to
22
an ultimate user or research subject by or pursuant to the
23
lawful order of a prescriber, including the prescribing,
24
administering, packaging, labeling, or compounding necessary
25
to prepare the substance for that delivery.
26

(q) "Dispenser" means a practitioner who dispenses.

SB0271
- 46 -
LRB104 03116 AAS 13137 b
1

(r) "Distribute" means to deliver, other than by
2
administering or dispensing, a controlled substance.
3

(s) "Distributor" means a person who distributes.
4

(t) "Drug" means (1) substances recognized as drugs in the
5
official United States Pharmacopoeia, Official Homeopathic
6
Pharmacopoeia of the United States, or official National
7
Formulary, or any supplement to any of them; (2) substances
8
intended for use in diagnosis, cure, mitigation, treatment, or
9
prevention of disease in man or animals; (3) substances (other
10
than food) intended to affect the structure of any function of
11
the body of man or animals and (4) substances intended for use
12
as a component of any article specified in clause (1), (2), or
13
(3) of this subsection. It does not include devices or their
14
components, parts, or accessories.
15

(t-3) "Electronic health record" or "EHR" means an
16
electronic record of health-related information on an
17
individual that is created, gathered, managed, and consulted
18
by authorized health care clinicians and staff.
19

(t-3.5) "Electronic health record system" or "EHR system"
20
means any computer-based system or combination of federally
21
certified Health IT Modules (defined at 42 CFR 170.102 or its
22
successor) used as a repository for electronic health records
23
and accessed or updated by a prescriber or authorized
24
surrogate in the ordinary course of his or her medical
25
practice. For purposes of connecting to the Prescription
26
Information Library maintained by the Bureau of Pharmacy and

SB0271
- 47 -
LRB104 03116 AAS 13137 b
1
Clinical Support Systems or its successor, an EHR system may
2
connect to the Prescription Information Library directly or
3
through all or part of a computer program or system that is a
4
federally certified Health IT Module maintained by a third
5
party and used by the EHR system to secure access to the
6
database.
7

(t-4) "Emergency medical services personnel" has the
8
meaning ascribed to it in the Emergency Medical Services (EMS)
9
Systems Act.
10

(t-5) "Euthanasia agency" means an entity certified by the
11
Department of Financial and Professional Regulation for the
12
purpose of animal euthanasia that holds an animal control
13
facility license or animal shelter license under the Animal
14
Welfare Act. A euthanasia agency is authorized to purchase,
15
store, possess, and utilize Schedule II nonnarcotic and
16
Schedule III nonnarcotic drugs for the sole purpose of animal
17
euthanasia.
18

(t-10) "Euthanasia drugs" means Schedule II or Schedule
19
III substances (nonnarcotic controlled substances) that are
20
used by a euthanasia agency for the purpose of animal
21
euthanasia.
22

(u) "Good faith" means the prescribing or dispensing of a
23
controlled substance by a practitioner in the regular course
24
of professional treatment to or for any person who is under his
25
or her treatment for a pathology or condition other than that
26
individual's physical or psychological dependence upon a

SB0271
- 48 -
LRB104 03116 AAS 13137 b
1
controlled substance, except as provided herein: and
2
application of the term to a pharmacist shall mean the
3
dispensing of a controlled substance pursuant to the
4
prescriber's order which in the professional judgment of the
5
pharmacist is lawful. The pharmacist shall be guided by
6
accepted professional standards, including, but not limited
7
to, the following, in making the judgment:
8

(1) lack of consistency of prescriber-patient
9

relationship,
10

(2) frequency of prescriptions for same drug by one
11

prescriber for large numbers of patients,
12

(3) quantities beyond those normally prescribed,
13

(4) unusual dosages (recognizing that there may be
14

clinical circumstances where more or less than the usual
15

dose may be used legitimately),
16

(5) unusual geographic distances between patient,
17

pharmacist and prescriber,
18

(6) consistent prescribing of habit-forming drugs.
19

(u-0.5) "Hallucinogen" means a drug that causes markedly
20
altered sensory perception leading to hallucinations of any
21
type.
22

(u-1) "Home infusion services" means services provided by
23
a pharmacy in compounding solutions for direct administration
24
to a patient in a private residence, long-term care facility,
25
or hospice setting by means of parenteral, intravenous,
26
intramuscular, subcutaneous, or intraspinal infusion.

SB0271
- 49 -
LRB104 03116 AAS 13137 b
1

(u-5) "Illinois State Police" means the Illinois State
2
Police or its successor agency.
3

(v) "Immediate precursor" means a substance:
4

(1) which the Department has found to be and by rule
5

designated as being a principal compound used, or produced
6

primarily for use, in the manufacture of a controlled
7

substance;
8

(2) which is an immediate chemical intermediary used
9

or likely to be used in the manufacture of such controlled
10

substance; and
11

(3) the control of which is necessary to prevent,
12

curtail or limit the manufacture of such controlled
13

substance.
14

(w) "Instructional activities" means the acts of teaching,
15
educating or instructing by practitioners using controlled
16
substances within educational facilities approved by the State
17
Board of Education or its successor agency.
18

(x) "Local authorities" means a duly organized State,
19
County or Municipal peace unit or police force.
20

(y) "Look-alike substance" means a substance, other than a
21
controlled substance which (1) by overall dosage unit
22
appearance, including shape, color, size, markings or lack
23
thereof, taste, consistency, or any other identifying physical
24
characteristic of the substance, would lead a reasonable
25
person to believe that the substance is a controlled
26
substance, or (2) is expressly or impliedly represented to be

SB0271
- 50 -
LRB104 03116 AAS 13137 b
1
a controlled substance or is distributed under circumstances
2
which would lead a reasonable person to believe that the
3
substance is a controlled substance. For the purpose of
4
determining whether the representations made or the
5
circumstances of the distribution would lead a reasonable
6
person to believe the substance to be a controlled substance
7
under this clause (2) of subsection (y), the court or other
8
authority may consider the following factors in addition to
9
any other factor that may be relevant:
10

(a) statements made by the owner or person in control
11

of the substance concerning its nature, use or effect;
12

(b) statements made to the buyer or recipient that the
13

substance may be resold for profit;
14

(c) whether the substance is packaged in a manner
15

normally used for the illegal distribution of controlled
16

substances;
17

(d) whether the distribution or attempted distribution
18

included an exchange of or demand for money or other
19

property as consideration, and whether the amount of the
20

consideration was substantially greater than the
21

reasonable retail market value of the substance.
22

Clause (1) of this subsection (y) shall not apply to a
23
noncontrolled substance in its finished dosage form that was
24
initially introduced into commerce prior to the initial
25
introduction into commerce of a controlled substance in its
26
finished dosage form which it may substantially resemble.

SB0271
- 51 -
LRB104 03116 AAS 13137 b
1

Nothing in this subsection (y) prohibits the dispensing or
2
distributing of noncontrolled substances by persons authorized
3
to dispense and distribute controlled substances under this
4
Act, provided that such action would be deemed to be carried
5
out in good faith under subsection (u) if the substances
6
involved were controlled substances.
7

Nothing in this subsection (y) or in this Act prohibits
8
the manufacture, preparation, propagation, compounding,
9
processing, packaging, advertising or distribution of a drug
10
or drugs by any person registered pursuant to Section 510 of
11
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
12

(y-1) "Mail-order pharmacy" means a pharmacy that is
13
located in a state of the United States that delivers,
14
dispenses or distributes, through the United States Postal
15
Service or other common carrier, to Illinois residents, any
16
substance which requires a prescription.
17

(z) "Manufacture" means the production, preparation,
18
propagation, compounding, conversion or processing of a
19
controlled substance other than methamphetamine, either
20
directly or indirectly, by extraction from substances of
21
natural origin, or independently by means of chemical
22
synthesis, or by a combination of extraction and chemical
23
synthesis, and includes any packaging or repackaging of the
24
substance or labeling of its container, except that this term
25
does not include:
26

(1) by an ultimate user, the preparation or

SB0271
- 52 -
LRB104 03116 AAS 13137 b
1

compounding of a controlled substance for his or her own
2

use;
3

(2) by a practitioner, or his or her authorized agent
4

under his or her supervision, the preparation,
5

compounding, packaging, or labeling of a controlled
6

substance:
7

(a) as an incident to his or her administering or
8

dispensing of a controlled substance in the course of
9

his or her professional practice; or
10

(b) as an incident to lawful research, teaching or
11

chemical analysis and not for sale; or
12

(3) the packaging, repackaging, or labeling of drugs
13

only to the extent permitted under the Illinois Drug Reuse
14

Opportunity Program Act.
15

(z-1) (Blank).
16

(z-5) "Medication shopping" means the conduct prohibited
17
under subsection (a) of Section 314.5 of this Act.
18

(z-10) "Mid-level practitioner" means (i) a physician
19
assistant
who has been delegated authority to prescribe
20
through a written delegation of authority by a physician
21
licensed to practice medicine in all of its branches, in
22
accordance with Section 7.5 of the Physician Assistant
23
Practice Act of 1987
, (ii) an advanced practice registered
24
nurse who has been delegated authority to prescribe through a
25
written delegation of authority by a physician licensed to
26
practice medicine in all of its branches or by a podiatric

SB0271
- 53 -
LRB104 03116 AAS 13137 b
1
physician, in accordance with Section 65-40 of the Nurse
2
Practice Act, (iii) an advanced practice registered nurse
3
certified as a nurse practitioner, nurse midwife, or clinical
4
nurse specialist who has been granted authority to prescribe
5
by a hospital affiliate in accordance with Section 65-45 of
6
the Nurse Practice Act, (iv) an animal euthanasia agency, or
7
(v) a prescribing psychologist.
8

(aa) "Narcotic drug" means any of the following, whether
9
produced directly or indirectly by extraction from substances
10
of vegetable origin, or independently by means of chemical
11
synthesis, or by a combination of extraction and chemical
12
synthesis:
13

(1) opium, opiates, derivatives of opium and opiates,
14

including their isomers, esters, ethers, salts, and salts
15

of isomers, esters, and ethers, whenever the existence of
16

such isomers, esters, ethers, and salts is possible within
17

the specific chemical designation; however the term
18

"narcotic drug" does not include the isoquinoline
19

alkaloids of opium;
20

(2) (blank);
21

(3) opium poppy and poppy straw;
22

(4) coca leaves, except coca leaves and extracts of
23

coca leaves from which substantially all of the cocaine
24

and ecgonine, and their isomers, derivatives and salts,
25

have been removed;
26

(5) cocaine, its salts, optical and geometric isomers,

SB0271
- 54 -
LRB104 03116 AAS 13137 b
1

and salts of isomers;
2

(6) ecgonine, its derivatives, their salts, isomers,
3

and salts of isomers;
4

(7) any compound, mixture, or preparation which
5

contains any quantity of any of the substances referred to
6

in subparagraphs (1) through (6).
7

(bb) "Nurse" means a registered nurse licensed under the
8
Nurse Practice Act.
9

(cc) (Blank).
10

(dd) "Opiate" means a drug derived from or related to
11
opium.
12

(ee) "Opium poppy" means the plant of the species Papaver
13
somniferum L., except its seeds.
14

(ee-5) "Oral dosage" means a tablet, capsule, elixir, or
15
solution or other liquid form of medication intended for
16
administration by mouth, but the term does not include a form
17
of medication intended for buccal, sublingual, or transmucosal
18
administration.
19

(ff) "Parole and Pardon Board" means the Parole and Pardon
20
Board of the State of Illinois or its successor agency.
21

(gg) "Person" means any individual, corporation,
22
mail-order pharmacy, government or governmental subdivision or
23
agency, business trust, estate, trust, partnership or
24
association, or any other entity.
25

(hh) "Pharmacist" means any person who holds a license or
26
certificate of registration as a registered pharmacist, a

SB0271
- 55 -
LRB104 03116 AAS 13137 b
1
local registered pharmacist or a registered assistant
2
pharmacist under the Pharmacy Practice Act.
3

(ii) "Pharmacy" means any store, ship or other place in
4
which pharmacy is authorized to be practiced under the
5
Pharmacy Practice Act.
6

(ii-5) "Pharmacy shopping" means the conduct prohibited
7
under subsection (b) of Section 314.5 of this Act.
8

(ii-10) "Physician" (except when the context otherwise
9
requires) means a person licensed to practice medicine in all
10
of its branches.
11

(jj) "Poppy straw" means all parts, except the seeds, of
12
the opium poppy, after mowing.
13

(kk) "Practitioner" means a physician licensed to practice
14
medicine in all its branches, dentist, optometrist, podiatric
15
physician, veterinarian, scientific investigator, pharmacist,
16
physician assistant, advanced practice registered nurse,
17
licensed practical nurse, registered nurse, emergency medical
18
services personnel, hospital, laboratory, or pharmacy, or
19
other person licensed, registered, or otherwise lawfully
20
permitted by the United States or this State to distribute,
21
dispense, conduct research with respect to, administer or use
22
in teaching or chemical analysis, a controlled substance in
23
the course of professional practice or research.
24

(ll) "Pre-printed prescription" means a written
25
prescription upon which the designated drug has been indicated
26
prior to the time of issuance; the term does not mean a written

SB0271
- 56 -
LRB104 03116 AAS 13137 b
1
prescription that is individually generated by machine or
2
computer in the prescriber's office.
3

(mm) "Prescriber" means a physician licensed to practice
4
medicine in all its branches, dentist, optometrist,
5
prescribing psychologist licensed under Section 4.2 of the
6
Clinical Psychologist Licensing Act with prescriptive
7
authority delegated under Section 4.3 of the Clinical
8
Psychologist Licensing Act, podiatric physician, or
9
veterinarian who issues a prescription, a physician assistant
10
who issues a prescription for a controlled substance in
11
accordance with Section 303.05,
a written delegation, and a
12
written collaborative agreement required under Section 7.5 of
13
the Physician Assistant Practice Act of 1987,
an advanced
14
practice registered nurse with prescriptive authority
15
delegated under Section 65-40 of the Nurse Practice Act and in
16
accordance with Section 303.05, a written delegation, and a
17
written collaborative agreement under Section 65-35 of the
18
Nurse Practice Act, an advanced practice registered nurse
19
certified as a nurse practitioner, nurse midwife, or clinical
20
nurse specialist who has been granted authority to prescribe
21
by a hospital affiliate in accordance with Section 65-45 of
22
the Nurse Practice Act and in accordance with Section 303.05,
23
or an advanced practice registered nurse certified as a nurse
24
practitioner, nurse midwife, or clinical nurse specialist who
25
has full practice authority pursuant to Section 65-43 of the
26
Nurse Practice Act.

SB0271
- 57 -
LRB104 03116 AAS 13137 b
1

(nn) "Prescription" means a written, facsimile, or oral
2
order, or an electronic order that complies with applicable
3
federal requirements, of a physician licensed to practice
4
medicine in all its branches, dentist, podiatric physician or
5
veterinarian for any controlled substance, of an optometrist
6
in accordance with Section 15.1 of the Illinois Optometric
7
Practice Act of 1987, of a prescribing psychologist licensed
8
under Section 4.2 of the Clinical Psychologist Licensing Act
9
with prescriptive authority delegated under Section 4.3 of the
10
Clinical Psychologist Licensing Act, of a physician assistant
11
for a controlled substance in accordance with Section 303.05,
12
a written delegation, and a written collaborative agreement
13
required under Section 7.5 of the Physician Assistant Practice
14
Act of 1987, of an advanced practice registered nurse with
15
prescriptive authority delegated under Section 65-40 of the
16
Nurse Practice Act who issues a prescription for a controlled
17
substance in accordance with Section 303.05, a written
18
delegation, and a written collaborative agreement under
19
Section 65-35 of the Nurse Practice Act, of an advanced
20
practice registered nurse certified as a nurse practitioner,
21
nurse midwife, or clinical nurse specialist who has been
22
granted authority to prescribe by a hospital affiliate in
23
accordance with Section 65-45 of the Nurse Practice Act and in
24
accordance with Section 303.05 when required by law, or of an
25
advanced practice registered nurse certified as a nurse
26
practitioner, nurse midwife, or clinical nurse specialist who

SB0271
- 58 -
LRB104 03116 AAS 13137 b
1
has full practice authority pursuant to Section 65-43 of the
2
Nurse Practice Act.
3

(nn-5) "Prescription Information Library" (PIL) means an
4
electronic library that contains reported controlled substance
5
data.
6

(nn-10) "Prescription Monitoring Program" (PMP) means the
7
entity that collects, tracks, and stores reported data on
8
controlled substances and select drugs pursuant to Section
9
316.
10

(oo) "Production" or "produce" means manufacture,
11
planting, cultivating, growing, or harvesting of a controlled
12
substance other than methamphetamine.
13

(pp) "Registrant" means every person who is required to
14
register under Section 302 of this Act.
15

(qq) "Registry number" means the number assigned to each
16
person authorized to handle controlled substances under the
17
laws of the United States and of this State.
18

(qq-5) "Secretary" means, as the context requires, either
19
the Secretary of the Department or the Secretary of the
20
Department of Financial and Professional Regulation, and the
21
Secretary's designated agents.
22

(rr) "State" includes the State of Illinois and any state,
23
district, commonwealth, territory, insular possession thereof,
24
and any area subject to the legal authority of the United
25
States of America.
26

(rr-5) "Stimulant" means any drug that (i) causes an

SB0271
- 59 -
LRB104 03116 AAS 13137 b
1
overall excitation of central nervous system functions, (ii)
2
causes impaired consciousness and awareness, and (iii) can be
3
habit-forming or lead to a substance use disorder, including,
4
but not limited to, amphetamines and their analogs,
5
methylphenidate and its analogs, cocaine, and phencyclidine
6
and its analogs.
7

(rr-10) "Synthetic drug" includes, but is not limited to,
8
any synthetic cannabinoids or piperazines or any synthetic
9
cathinones as provided for in Schedule I.
10

(ss) "Ultimate user" means a person who lawfully possesses
11
a controlled substance for his or her own use or for the use of
12
a member of his or her household or for administering to an
13
animal owned by him or her or by a member of his or her
14
household.
15
(Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
16
102-813, eff. 5-13-22; 103-881, eff. 1-1-25
.)

17

(720 ILCS 570/303.05)
18

Sec. 303.05.
Mid-level practitioner registration.
19

(a) The Department of Financial and Professional
20
Regulation shall register licensed physician assistants,
21
licensed advanced practice registered nurses, and prescribing
22
psychologists licensed under Section 4.2 of the Clinical
23
Psychologist Licensing Act to prescribe and dispense
24
controlled substances under Section 303 and euthanasia
25
agencies to purchase, store, or administer animal euthanasia

SB0271
- 60 -
LRB104 03116 AAS 13137 b
1
drugs under the following circumstances:
2

(1) with respect to physician assistants,
3

(A) the physician assistant has been delegated
4

written authority to prescribe any Schedule III
5

through V controlled substances by a physician
6

licensed to practice medicine in all its branches in
7

accordance with Section 7.5 of the Physician Assistant
8

Practice Act of 1987; and the physician assistant has
9

completed the appropriate application forms and has
10

paid the required fees as set by rule; or

11

(B) the physician assistant has been delegated
12

authority by a collaborating physician licensed to
13

practice medicine in all its branches to prescribe or
14

dispense Schedule II controlled substances through a
15

written delegation of authority and under the
16

following conditions:
17

(i) Specific Schedule II controlled substances
18

by oral dosage or topical or transdermal
19

application may be delegated, provided that the
20

delegated Schedule II controlled substances are
21

routinely prescribed by the collaborating
22

physician. This delegation must identify the
23

specific Schedule II controlled substances by
24

either brand name or generic name. Schedule II
25

controlled substances to be delivered by injection
26

or other route of administration may not be

SB0271
- 61 -
LRB104 03116 AAS 13137 b
1

delegated;
2

(ii) any delegation must be of controlled
3

substances prescribed by the collaborating
4

physician;
5

(iii) all prescriptions must be limited to no
6

more than a 30-day supply, with any continuation
7

authorized only after prior approval of the
8

collaborating physician;
9

(iv) the physician assistant must discuss the
10

condition of any patients for whom a controlled
11

substance is prescribed monthly with the
12

delegating physician;
13

(A)

(v)
the physician assistant must have
14

completed the appropriate application forms and paid
15

the required fees as set by rule;
16

(B)

(vi)
the physician assistant must provide
17

evidence of satisfactory completion of 45 contact
18

hours in pharmacology from any physician assistant
19

program accredited by the Accreditation Review
20

Commission on Education for the Physician Assistant
21

(ARC-PA), or its predecessor agency, for any new
22

license issued with Schedule II authority after the
23

effective date of this amendatory Act of the 97th
24

General Assembly; and
25

(C)

(vii)
the physician assistant must annually
26

complete at least 5 hours of continuing education in

SB0271
- 62 -
LRB104 03116 AAS 13137 b
1

pharmacology;
2

(2) with respect to advanced practice registered
3

nurses who do not meet the requirements of Section 65-43
4

of the Nurse Practice Act,
5

(A) the advanced practice registered nurse has
6

been delegated authority to prescribe any Schedule III
7

through V controlled substances by a collaborating
8

physician licensed to practice medicine in all its
9

branches or a collaborating podiatric physician in
10

accordance with Section 65-40 of the Nurse Practice
11

Act. The advanced practice registered nurse has
12

completed the appropriate application forms and has
13

paid the required fees as set by rule; or
14

(B) the advanced practice registered nurse has
15

been delegated authority by a collaborating physician
16

licensed to practice medicine in all its branches to
17

prescribe or dispense Schedule II controlled
18

substances through a written delegation of authority
19

and under the following conditions:
20

(i) specific Schedule II controlled substances
21

by oral dosage or topical or transdermal
22

application may be delegated, provided that the
23

delegated Schedule II controlled substances are
24

routinely prescribed by the collaborating
25

physician. This delegation must identify the
26

specific Schedule II controlled substances by

SB0271
- 63 -
LRB104 03116 AAS 13137 b
1

either brand name or generic name. Schedule II
2

controlled substances to be delivered by injection
3

or other route of administration may not be
4

delegated;
5

(ii) any delegation must be of controlled
6

substances prescribed by the collaborating
7

physician;
8

(iii) all prescriptions must be limited to no
9

more than a 30-day supply, with any continuation
10

authorized only after prior approval of the
11

collaborating physician;
12

(iv) the advanced practice registered nurse
13

must discuss the condition of any patients for
14

whom a controlled substance is prescribed monthly
15

with the delegating physician or in the course of
16

review as required by Section 65-40 of the Nurse
17

Practice Act;
18

(v) the advanced practice registered nurse
19

must have completed the appropriate application
20

forms and paid the required fees as set by rule;
21

(vi) the advanced practice registered nurse
22

must provide evidence of satisfactory completion
23

of at least 45 graduate contact hours in
24

pharmacology for any new license issued with
25

Schedule II authority after the effective date of
26

this amendatory Act of the 97th General Assembly;

SB0271
- 64 -
LRB104 03116 AAS 13137 b
1

and
2

(vii) the advanced practice registered nurse
3

must annually complete 5 hours of continuing
4

education in pharmacology;
5

(2.5) with respect to advanced practice registered
6

nurses certified as nurse practitioners, nurse midwives,
7

or clinical nurse specialists who do not meet the
8

requirements of Section 65-43 of the Nurse Practice Act
9

practicing in a hospital affiliate,
10

(A) the advanced practice registered nurse
11

certified as a nurse practitioner, nurse midwife, or
12

clinical nurse specialist has been privileged to
13

prescribe any Schedule II through V controlled
14

substances by the hospital affiliate upon the
15

recommendation of the appropriate physician committee
16

of the hospital affiliate in accordance with Section
17

65-45 of the Nurse Practice Act, has completed the
18

appropriate application forms, and has paid the
19

required fees as set by rule; and
20

(B) an advanced practice registered nurse
21

certified as a nurse practitioner, nurse midwife, or
22

clinical nurse specialist has been privileged to
23

prescribe any Schedule II controlled substances by the
24

hospital affiliate upon the recommendation of the
25

appropriate physician committee of the hospital
26

affiliate, then the following conditions must be met:

SB0271
- 65 -
LRB104 03116 AAS 13137 b
1

(i) specific Schedule II controlled substances
2

by oral dosage or topical or transdermal
3

application may be designated, provided that the
4

designated Schedule II controlled substances are
5

routinely prescribed by advanced practice
6

registered nurses in their area of certification;
7

the privileging documents must identify the
8

specific Schedule II controlled substances by
9

either brand name or generic name; privileges to
10

prescribe or dispense Schedule II controlled
11

substances to be delivered by injection or other
12

route of administration may not be granted;
13

(ii) any privileges must be controlled
14

substances limited to the practice of the advanced
15

practice registered nurse;
16

(iii) any prescription must be limited to no
17

more than a 30-day supply;
18

(iv) the advanced practice registered nurse
19

must discuss the condition of any patients for
20

whom a controlled substance is prescribed monthly
21

with the appropriate physician committee of the
22

hospital affiliate or its physician designee; and
23

(v) the advanced practice registered nurse
24

must meet the education requirements of this
25

Section;
26

(3) with respect to animal euthanasia agencies, the

SB0271
- 66 -
LRB104 03116 AAS 13137 b
1

euthanasia agency has obtained a license from the
2

Department of Financial and Professional Regulation and
3

obtained a registration number from the Department; or
4

(4) with respect to prescribing psychologists, the
5

prescribing psychologist has been delegated authority to
6

prescribe any nonnarcotic Schedule III through V
7

controlled substances by a collaborating physician
8

licensed to practice medicine in all its branches in
9

accordance with Section 4.3 of the Clinical Psychologist
10

Licensing Act, and the prescribing psychologist has
11

completed the appropriate application forms and has paid
12

the required fees as set by rule.
13

(b) The mid-level practitioner shall only be licensed to
14
prescribe those schedules of controlled substances for which a
15
licensed physician has delegated prescriptive authority,
16
except that an animal euthanasia agency does not have any
17
prescriptive authority
and a physician assistant shall have
18
prescriptive authority in accordance with the Physician
19
Assistant Practice Act of 1987 without delegation by a
20
physician
.
An

A physician assistant and an
advanced practice
21
registered nurse
is

are
prohibited from prescribing
22
medications and controlled substances not set forth in the
23
required written delegation of authority or as authorized by
24
their practice Act.
25

(c) Upon completion of all registration requirements,
26
physician assistants, advanced practice registered nurses, and

SB0271
- 67 -
LRB104 03116 AAS 13137 b
1
animal euthanasia agencies may be issued a mid-level
2
practitioner controlled substances license for Illinois.
3

(d) A collaborating physician may, but is not required to,
4
delegate prescriptive authority to an advanced practice
5
registered nurse as part of a written collaborative agreement,
6
and the delegation of prescriptive authority shall conform to
7
the requirements of Section 65-40 of the Nurse Practice Act.
8

(e)
(Blank).

A collaborating physician may, but is not
9
required to, delegate prescriptive authority to a physician
10
assistant as part of a written collaborative agreement, and
11
the delegation of prescriptive authority shall conform to the
12
requirements of Section 7.5 of the Physician Assistant
13
Practice Act of 1987.

14

(f) Nothing in this Section shall be construed to prohibit
15
generic substitution.
16
(Source: P.A. 99-173, eff. 7-29-15; 100-453, eff. 8-25-17;
17
100-513, eff. 1-1-18; 100-863, eff. 8-14-18.)

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn